[{"id":"1f2d0edd-3aa3-4ee5-bf61-cd430b705bcf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03705858","created_at":"2021-01-18T18:09:32.951Z","updated_at":"2024-07-02T16:37:02.100Z","phase":"Phase 1","brief_title":"Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03705858","lead_sponsor":"Joseph Jurcic","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actimab-A (lintuzumab-Ac225) • Zamyl (lintuzumab)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 02/28/2019","primary_completion_date":" 02/28/2019","study_txt":" Completion: 02/28/2019","study_completion_date":" 02/28/2019","last_update_posted":"2019-03-08"}]